An interventional study of Blood sampling in Hepatitis C and Dried Blood Spot, sponsored by Institut Pasteur. Completed at 2 sites in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-01.
Sponsored by Institut Pasteur · Not applicable, Interventional, and Diagnostic
In Vietnam, the prevalence of hepatitis C virus (HCV) infection is estimated between 0.4% and 5%, which is much higher than the prevalence in Europe or in the USA. After HCV diagnosis, HCV viral load quantification is crucial in order to distinguish recovered from active (on-going) HCV infection and hence identify those who need antiviral treatment to cure HCV infection. HCV viral load quantification is also important to assess treatment efficacy.
Currently, anti-HCV antibodies detection is available around the country. However, access to confirmation of HCV viremia remains scarce particularly in decentralized areas. One of the reason is the limited number of laboratories able to perform this complex biological measurement; moreover, these laboratories are situated only in large urban centres.
Blood sampling using DBS could help overcome this difficulty of access to a laboratory, and widen access to HCV viral load monitoring.
The present MOVIDA Hep study aims at validating the use of DBS to measure HCV viral load as compared to plasma (gold standard). A secondary objective is to evaluate the measurement of HCV core antigen on DBS. For this, 315 patients need to be enrolled form outpatient clinics in Hanoi. The laboratory in charge of these measurements would be the virology laboratory of the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi (Vietnam).
The "Monitoring Of Viral load In Decentralised Area" (MOVIDA) project aims at giving access to viral load (VL) monitoring to the patients coming from remote areas using Dried Blood Spot as tool of sampling.
In resource-limited settings, many biological exams are not accessible to the entire population due to logistic and financial constraints. Regarding infection with hepatitis B and C viruses (HBV and HCV), serological screening tests are easy to perform and are available nationwide in either laboratory format or rapid diagnosis tests. However, hepatitis B DNA and C RNA assessment is not available in decentralised area as no laboratory is able to perform this complex biological measurement.
WHO, in their latest guidelines, recommends using dried blood spots (DBS) as an alternative to serum or plasma. Blood is easy to collect on DBS, either after veni- or capillary puncture. Capillary blood collection can be of great interest when venipuncture is complex, for example in injecting drug users (IDUs) in whom finding an accessible vein can be difficult. Then it is easily transferred, and at a low cost as it does not require a cold chain, to a laboratory able to perform the HCV VL quantification. As of today, little is known about the performance of standard commercial HCV diagnostic assays when using DBS and none of these studies were performed in routine setting in resource-limited setting.
In Vietnam, HCV seroprevalence in the general population is estimated between 0.4% and 5%, which is much higher than the prevalence in Europe or in the US. Genotype 1 is the more prevalent in Vietnam, genotype 6 that is only found in South East Asia is the second most frequent, but other genotypes are circulating . In Vietnam, HCV prevalence is much higher in the HIV-infected population and in injecting drug users (IDUs). Currently, anti-HCV antibodies detection is available around the country even if some difficulties remain. However, access to HCV HCV viral load measurement in routine remains scarce particularly in decentralized areas because the technique is complex, expensive and need well-trained personnel and high standard of equipment. Thus, HCV viral load measurement remains non accessible to the vast majority of patients diagnosed with HCV.
This study (MOVIDA Hep) aims at evaluating the quality of HCV VL monitoring when using DBS (collection of venous and capillary blood) as compared to plasma (gold standard), in routine condition and using the existing machines. This, to find out if DBS can be used for HCV viremia confirmation in Vietnam, in the virology laboratory of the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi (Vietnam) where these measurements would be performed.
2,356 studies on the registry are indexed under Hepatitis C; 101 are open to participants now.
This study's enrollment of 315 is above the median of 79 across 1,660 interventional studies indexed under Hepatitis C.
Browse Hepatitis C studies →Institut Pasteur is the lead sponsor of 98 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
Procedure: Blood sampling
Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
Quantification of HCV RNA on DBS compared to plasma as gold standard
Sensitivity and specificity of HCV RNA VL measured on DBS collected by venipuncture
Time frame: Up to 4 weeks
Quantification of HCV RNA measured on DBS using plasma as gold standard
Sensitivity and specificity of HCV RNA VL measured on DBS collected by finger prick
Time frame: Up to 4 weeks
Correlation between HCV RNA VL measured on DBS and on plasma.
Correlation between HCV RNA VL measured on DBS (collected by venipuncture and finger prick) and on plasma.
Time frame: Up to 6 months
Quantification of HCV core antigen using HCV RNA VL as gold standard
Sensitivity and specificity of HCV core antigen using HCV RNA VL as gold standard
Time frame: Up to 8 weeks
Correlation between HCV core antigen and HCV RNA VL on plasma
Correlation between HCV core antigen and HCV RNA VL, both measured on plasma.
Time frame: Up to 6 months
Quantification of HCV core antigen measured on DBS using HCV RNA VL measured on plasma as gold standard.
Sensitivity and specificity of HCV core antigen measured on DBS collected by venipuncture using HCV RNA VL measured on plasma as gold standard.
Time frame: Up to 8 weeks
Correlation between HCV core antigen measured on DBS and HCV RNA VL measured on plasma.
Correlation between HCV core antigen measured on DBS collected by venipuncture and HCV RNA VL measured on plasma.
Time frame: Up to 6 months
Plan to share: No
Ran from May 2019 to primary completion in Jul 2019, 2 months.
Of 166 interventional studies with no phase under Hepatitis C, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.